28
Oct
2019
Early Cancer Screening is Maturing. What Will It Mean for Drug Developers?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account. 
Share:
21
Oct
2019
Biotech’s film making exec behind ‘Jim Allison: Breakthrough’
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
8
Oct
2019
Join Me and a Biotech Team on the Trek of a Lifetime for Cancer Research
Earlier this year, I led a team of 27 biotech professionals to Mt. Kilimanjaro, the highest peak in Africa. Each of us committed to raise $50,000 for cancer research at Fred Hutch. We ended up raising $1.6 million. We had an amazing time together. We all made it to the top. I want to do it again. This time we’re...Read More
Share:
21
Aug
2019
An Unforgettable Experience: The Kilimanjaro Climb to Fight Cancer Yearbook
The Kilimanjaro Climb to Fight Cancer was a marvelous experience. In every way. Weeks later, I’m still absorbing what it means to scientists at Fred Hutch, and to the biotech community. To start, consider the numbers: Our team of 27 climbers raised $1,587,475 for cancer research More than 2,200 donors contributed from around the country 33 sponsors supported the cause...Read More
Share:
20
Aug
2019
As CAR-T Ranks Expand, Industry Scrambles to Solve Long-Standing Manufacturing Challenges
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
16
Jul
2019
As Cancer Immunotherapy Booms, Biomarkers Re-Emerge to Guide Treatment
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
11
Jul
2019
Better Cancer Treatment Through Better Information: Cindy Perettie on The Long Run
Today’s guest on The Long Run is Cindy Perettie. Cindy is the CEO of Cambridge, Mass.-based Foundation Medicine. This company does genomic analysis on tumors. If you know more of this molecular nitty-gritty information – things like the underlying gene mutations that send cancer cells into out-of-control growth sprees – then you ought to occasionally come up with more effective...Read More
Share:
30
May
2019
Third Rock and Friends Bet $110M On Thrive, a Hopkins-Inspired Cancer Screening Startup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
8
May
2019
Thank You, Biotech: Kili Climb to Fight Has Crushed Its $1m Goal for Cancer Research
Today, I want to say thank you. Thank you to the biotech community for your Incredibly Generous support of the Kilimanjaro Climb to Fight Cancer. You have enabled us to reach our goal of raising $1 million this year for lifesaving cancer research at Fred Hutch. Who are we? We are a team of 28 biotech executives and investors. 14...Read More
Share:
23
Apr
2019
3 Lessons for Success in Research: Reflections from AACR 2019
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
22
Apr
2019
The Gut Microbiome Modifies Immuno-Oncology Response, Suggesting Ways to Accelerate Activity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
9
Apr
2019
The Road Less Traveled in Glycoscience: Carolyn Bertozzi on The Long Run
Today’s guest on The Long Run is Carolyn Bertozzi. She is a professor of chemistry at Stanford University, and an entrepreneur. Her research is focused on glycans – the beautiful and bewilderingly complicated sugar molecule structures attached to proteins. These carbohydrates are often underappreciated by biologists, and “orthogonal” to the way many think. But glycans are known to play a...Read More
Share:
27
Feb
2019
Staying Resilient, Finding a Way Forward: Julia Owens on The Long Run
Julia Owens is today’s guest on The Long Run. Owens is the CEO of Ann Arbor, Michigan-based Millendo Therapeutics. This company develops drugs for rare endocrine disorders. Prader-Willi syndrome, a terrible genetic disorder that causes young people to develop voracious appetites and which leads to severe obesity, is the focus of the company’s lead drug candidate. It’s entering a pivotal...Read More
Share:
20
Feb
2019
The Boston Cancer Summit and SF Cancer Summit. See the Agenda & Get Your Tickets
The Boston Cancer Summit is loaded with a stellar lineup of speakers on Apr. 16. Same deal with the San Francisco Cancer Summit on Apr. 18. I’m excited to announce the agendas for these special idea-and-networking forums. Hal Barron of GSK, David Schenkein of GV, Cindy Perettie of Foundation Medicine, and Ira Mellman of Genentech are a few of the...Read More
Share:
6
Feb
2019
Get Tickets Now: The Cancer Summit Series is Coming to Boston, SF, Seattle
We live in a time of tremendous possibility for cancer R&D. Checkpoint inhibitors, cell therapies, molecular diagnostics that catch cancer early and can guide effective custom treatment – these fields are brimming with progress. All were considered speculative at best a decade ago. The science has never been more promising. Yet pricing and access to this new world of cancer...Read More
Share:
20
Dec
2018
Relay Therapeutics Hauls in $400M to Push Frontier in Computational Drug Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
12
Dec
2018
First Everest, Now Kilimanjaro: Climb With Me and a Great Biotech Team to Fight Cancer
Summiting the highest peak in the world and raising $340,000 for cancer research at Fred Hutch was the start. It was the start of something bigger. Today, I’m overjoyed to say that an outstanding team of biotech executives and investors will join me on the Kilimanjaro Climb to Fight Cancer. This will be a 7-day expedition to the summit of...Read More
Share:
11
Dec
2018
OSI Veterans, and Versant Ventures, Unveil Startup To Fight Allosteric Resistance Mutations in Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
21
Sep
2018
WuXi Eyes A Fresh $1B, California Aims at AbbVie, and MSK’s Industry Ties in the Spotlight
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
Share:
17
Jul
2018
Nine Observations on Leadership and Teamwork from Mt. Everest
Most of you have heard by now that I reached the summit of Mt. Everest, the highest mountain in the world, on May 22. Not only was this a dream come true, it was the culmination of my charity fundraising campaign, the Everest Climb to Fight Cancer. It fetched $339,000 for cancer research at the Fred Hutch, a leading center...Read More
Share: